Enhancing Nutraceutical Bioavailability with Bilosomes:
A Comprehensive Review
Prakash Nathaniel Kumar Sarella*, Vinny Therissa Mangam
Department of Pharmacy, Aditya College of Pharmacy,
ADB Road, Surampalem, Kakinada - 533437, Andhra Pradesh, India.
*Corresponding Author E-mail: sarellaprakash@acop.edu.in
ABSTRACT:
Nutraceuticals, encompassing vitamins, minerals, and dietary supplements, play a pivotal role in promoting health and wellness. However, their therapeutic efficacy is often hindered by poor bioavailability. Bilosomes, a burgeoning lipid-based nanocarrier, have emerged as a promising solution to overcome this challenge. This comprehensive review explores the potential of bilosomes as carriers for enhancing the bioavailability of nutraceuticals, shedding light on their formulation, characterization, mechanisms of action, safety considerations, and future prospects. The review begins by delineating the significance of nutraceuticals in promoting well-being and discusses the obstacles associated with their delivery. It subsequently introduces bilosomes, lipid vesicles equipped with bile salts, and elucidates their advantages over traditional delivery systems. A comparative analysis with other lipid-based carriers underscores the unique attributes that make bilosomes an attractive choice for nutraceutical delivery. A deeper dive into bilosome formulation and characterization provides insights into lipid composition, encapsulation techniques, and physicochemical characterization methods. Factors influencing bilosome stability and bioavailability, including size, surface charge, and interactions with physiological barriers, are comprehensively reviewed. Safety and toxicological considerations related to bilosome-based nutraceutical delivery are meticulously examined, drawing from preclinical and clinical studies. Regulatory aspects pertinent to bilosome incorporation in nutraceutical products are outlined. Future perspectives delve into emerging trends, formulation challenges, and the potential for personalized nutrition with bilosomes. In conclusion, this review underscores the transformative potential of bilosomes in enhancing nutraceutical bioavailability, opening new vistas in the field of personalized nutrition and health promotion.
KEYWORDS: Bilosomes, Nutraceuticals, Bioavailability, Lipid-based nanocarriers, Personalized nutrition.
INTRODUCTION:
Nutraceuticals, which encompass vitamins, minerals, dietary supplements, and bioactive compounds found in foods, have gained immense popularity due to their potential health benefits. They offer a bridge between nutrition and pharmaceuticals, holding promise for preventing and managing various health conditions1,2.
However, the effectiveness of nutraceuticals is often hampered by their limited bioavailability, which can result from factors like poor solubility, instability, and inefficient absorption in the gastrointestinal tract. Enhancing the bioavailability of nutraceuticals is a critical challenge in the field of nutrition and healthcare3. In recent years, researchers have explored innovative delivery systems to address these limitations. Among them, bilosomes, which are lipid-based vesicles incorporating bile salts, have emerged as a novel and promising strategy. Bilosomes have shown potential in improving the solubility, stability, and absorption of nutraceuticals, making them an attractive option for enhancing the therapeutic efficacy of these compounds4.
The primary objective of this review is to provide a comprehensive overview of the potential of bilosomes as carriers for improving the bioavailability of nutraceuticals, vitamins, and dietary supplements. This systematic exploration of bilosomes in the context of nutraceutical delivery aims to contribute valuable insights to researchers, healthcare professionals, and the nutraceutical industry.
Nutraceuticals and their importance:
Nutraceuticals represent a unique category of bioactive compounds that bridge the gap between nutrition and pharmaceuticals. These substances, found in various foods and dietary supplements, offer potential health benefits beyond basic nutritional value. They have gained increasing recognition and popularity due to their role in promoting wellness, preventing diseases, and improving overall health5. Understanding the importance of nutraceuticals is essential in appreciating their potential in healthcare and personalized nutrition.
1. Classification:
Nutraceuticals encompass a diverse range of compounds, and their classification can be based on their functional properties:
Vitamins and Minerals:
Essential micronutrients like vitamins (e.g., vitamin C, vitamin D) and minerals (e.g., calcium, zinc) play vital roles in maintaining health and preventing deficiencies6.
Phytochemicals:
These bioactive compounds are naturally occurring in plants and include polyphenols (e.g., flavonoids, resveratrol), carotenoids (e.g., beta-carotene), and glucosinolates7.
Amino Acids and Proteins:
Certain amino acids and proteins, such as branched-chain amino acids (BCAAs) and collagen, are used for various health benefits such as muscle support and skin health8.
Omega-3 Fatty Acids:
Omega-3s, found in fish oil and flaxseed, are well-known for their cardiovascular and anti-inflammatory properties9.
Probiotics and Prebiotics:
These support gut health by promoting beneficial gut bacteria and aiding digestion10.
Herbal Extracts:
Extracts from herbs and botanicals (e.g., ginseng, echinacea) are used for various therapeutic purposes11.
2. Health Benefits of Nutraceuticals:
Nutraceuticals offer a wide array of health benefits, which can vary depending on the specific compound. These benefits include:
Disease Prevention:
Some nutraceuticals are associated with a reduced risk of chronic diseases such as heart disease, diabetes, and certain types of cancer12.
Immune Support:
Nutraceuticals like vitamin C and zinc enhance the immune system's function, aiding in the prevention and treatment of infections13.
Antioxidant Properties:
Many nutraceuticals, particularly phytochemicals, exhibit strong antioxidant activity, protecting cells from oxidative damage and inflammation14.
Cognitive Health:
Nutraceuticals like omega-3 fatty acids and certain herbs have been linked to improved cognitive function and reduced risk of neurodegenerative diseases15.
Joint and Bone Health:
Nutraceuticals like glucosamine and calcium support joint health and bone density16.
Challenges in Nutraceutical Delivery:
While the health benefits of nutraceuticals are well-documented, their effectiveness in vivo can be limited by various challenges in delivery and absorption6–9,11. These challenges include:
Poor Solubility:
Many nutraceuticals have limited solubility in water, making it difficult for the body to absorb them efficiently6.
Low Bioavailability:
Nutraceuticals may undergo rapid metabolism in the digestive system, reducing their bioavailability and therapeutic efficacy7.
Gastrointestinal Degradation:
Some nutraceuticals are vulnerable to degradation in the acidic environment of the stomach8.
Variable Absorption:
Individual variations in gut physiology can lead to inconsistent absorption of nutraceuticals9.
Interactions with Food:
The presence of certain foods or dietary components can interfere with the absorption of specific nutraceuticals11.
Bilosomes: An Innovative Delivery System:
Bilosomes, a relatively novel and innovative lipid-based drug delivery system, have garnered significant attention in the field of pharmaceuticals and nutraceuticals. These unique carriers belong to the broader category of vesicular systems, similar to liposomes, but with a distinguishing feature: the inclusion of bile salts in their lipid bilayer. The integration of bile salts makes bilosomes particularly well-suited for enhancing the bioavailability of a wide range of compounds, including nutraceuticals, vitamins, and dietary supplements17.
Bilosomes possess a bilayer structure, like liposomes, comprising phospholipids, cholesterol, and bile salts. The incorporation of bile salts not only provides stability to the bilosome structure but also imparts some remarkable advantages that make them a promising choice for delivering nutraceuticals18. The structure of bilosome loaded with nutraceuticals is shown in Figure 1.
Figure 1: Bilosome Structure
Advantages of Bilosomes in Nutraceutical Delivery:
a) Enhanced Solubility:
One of the primary challenges in nutraceutical delivery is the poor solubility of many bioactive compounds. Bilosomes, owing to their unique composition, have the capacity to solubilize both hydrophilic and hydrophobic nutraceuticals, ensuring that a broader range of compounds can be effectively delivered19.
b) Improved Bioavailability:
Bilosomes are designed to improve the bioavailability of encapsulated compounds. The presence of bile salts aids in emulsifying and breaking down lipophilic substances, facilitating their absorption in the gastrointestinal tract. This leads to increased uptake and utilization of the nutraceuticals by the body20.
c) Stability Enhancement:
The inclusion of bile salts enhances the stability of bilosomes, preventing aggregation or fusion of vesicles during storage and transit. This stability ensures the prolonged shelf-life of nutraceutical formulations21.
d) Targeted Delivery:
Bilosomes can be designed for targeted delivery, enabling specific nutraceuticals to reach particular sites in the body. This feature is particularly valuable in cases where localized delivery is required, such as in addressing gut-related issues or targeting specific tissues or organs22,23.
e) Compatibility with Various Compounds:
Bilosomes can accommodate a wide range of nutraceuticals, regardless of their physicochemical properties. This adaptability makes bilosomes a versatile carrier system for different types of nutraceuticals and dietary supplements24.
Comparison with Other Lipid-Based Carriers:
In the realm of lipid-based carriers for nutraceutical delivery, bilosomes are distinctive and hold advantages over some of the other established systems, such as liposomes and niosomes:
a) Superior Stability: Bilosomes, with the inclusion of bile salts, often exhibit better stability than traditional liposomes, which can be prone to aggregation and leakage of encapsulated compounds25.
b) Enhanced Solubility: Unlike some niosomal systems, bilosomes can effectively solubilize both hydrophilic and lipophilic nutraceuticals, offering a broader applicability26.
c) Improved Bioavailability: Bilosomes generally demonstrate better bioavailability enhancement for nutraceuticals compared to conventional liposomes, owing to the presence of bile salts that aid in digestion and absorption27.
Formulation and characterization of bilosomes:
Bilosomes, as promising carriers for enhancing the bioavailability of nutraceuticals, demand meticulous attention to their formulation and thorough characterization. This section delves into the key aspects of bilosome formulation and the techniques used for their characterization28.
1. Lipid Composition and Selection:
The lipid composition of bilosomes is a critical determinant of their performance as nutraceutical delivery systems. Careful selection of lipids influences bilosome stability, drug encapsulation efficiency, and bioavailability enhancement29. Some considerations in lipid composition include:
Phospholipids: Phosphatidylcholine and phosphatidylserine are commonly used phospholipids in bilosome formulation. The choice of phospholipid affects bilosome size, charge, and membrane fluidity30.
Table 1: Common Bilosome Formulation Ingredients
Ingredient |
Function in Bilosome Formulation |
Phospholipids |
Major Structural Component: Forms the lipid bilayer, providing structural integrity to bilosomes. Commonly used phospholipids include phosphatidylcholine (PC), phosphatidylserine (PS), and others30. |
Cholesterol |
Stabilizer: Enhances bilosome stability and controls membrane fluidity, preventing aggregation and leakage34. |
Bile Salts |
Enhancer of Solubility: Facilitates the solubilization of both hydrophilic and lipophilic nutraceuticals within the bilosome, improving overall drug loading and absorption32. |
Surfactants |
Emulsification: May be used to further stabilize bilosomes and enhance their emulsification properties33. |
Antioxidants |
Protection: Added to prevent oxidative degradation of bilosome components and the encapsulated nutraceuticals. |
pH Modifiers |
pH Adjustment: Used to maintain the desired pH of bilosome formulations to ensure stability and compatibility with physiological conditions. |
Targeting Ligands |
Targeted Delivery: Ligands, such as antibodies or peptides, can be incorporated to enable targeted delivery of bilosomes to specific cells or tissues. |
Cholesterol:
Cholesterol is often added to lipid bilayers to enhance bilosome stability and modulate membrane fluidity. It plays a crucial role in maintaining the integrity of bilosomes31.
Bile Salts:
The type and concentration of bile salts incorporated into the bilosome formulation can be adjusted to optimize the solubility and bioavailability of specific nutraceuticals32.
Additional Lipids:
Other lipids, such as fatty acids or surfactants, may be included to further tailor the bilosome properties to the encapsulated nutraceuticals33. The common ingredients used in the formulation of Bilosomes and their purpose is listed out in Table 1.
2. Encapsulation Methods for Nutraceuticals:
The encapsulation of nutraceuticals within bilosomes is a critical step that influences their therapeutic effectiveness35. Several methods can be employed to encapsulate nutraceuticals efficiently:
Thin Film Hydration:
This method involves dissolving lipids and the nutraceutical of interest in an organic solvent to form a thin lipid film. Hydration with an aqueous phase then results in the formation of bilosomes with the nutraceutical encapsulated within the lipid bilayer36.
Reverse Phase Evaporation:
In this approach, lipids and the nutraceutical are dissolved in an organic solvent. The addition of an aqueous phase and subsequent evaporation of the organic solvent yields bilosomes with an aqueous core containing the nutraceutical37.
Ethanol Injection:
Here, lipids, nutraceutical, and bile salts are dissolved in ethanol and then rapidly injected into an aqueous medium. The precipitation of lipids and bile salts leads to bilosome formation with encapsulated nutraceuticals38.
The choice of encapsulation method depends on the physicochemical properties of the nutraceutical, the desired release profile, and the scalability of the process.
3. Physicochemical Characterization Techniques:
Accurate characterization of bilosomes is essential to assess their quality, stability, and performance. Various physicochemical techniques are employed for this purpose:
Particle Size Analysis:
Dynamic light scattering (DLS) or nanoparticle tracking analysis (NTA) is used to determine the size distribution of bilosomes. Size plays a critical role in their bioavailability and potential for targeted delivery39.
Zeta Potential Measurement:
Zeta potential provides information about the surface charge of bilosomes, which influences their stability and interaction with biological systems40.
Morphology Evaluation:
Scanning electron microscopy (SEM) or transmission electron microscopy (TEM) helps visualize the morphology and structural integrity of bilosomes29.
Encapsulation Efficiency:
This quantifies the amount of nutraceutical encapsulated within bilosomes and is typically determined through techniques like high-performance liquid chromatography (HPLC) or UV spectrophotometry30.
In vitro Release Studies:
Release profiles of nutraceuticals from bilosomes are assessed in simulated physiological conditions to understand their release kinetics and potential for controlled delivery34.
Factors Influencing Bilosome Stability And Bioavailability:
The stability and bioavailability of bilosomes, as carriers for delivering nutraceuticals and dietary supplements, are influenced by various factors32. Various factors that play a crucial role in determining the effectiveness of bilosome-based nutraceutical delivery are:
a) Lipid Composition:
The choice of lipids in bilosome formulation significantly impacts their stability. Appropriate lipid composition, including the type of phospholipids and the presence of cholesterol, is essential for maintaining bilosome integrity. Typical lipid composition may consist of 70-90% phosphatidylcholine, 10-20% cholesterol, and 0-10% bile salts30.
b) Bile Salt Concentration:
The concentration and type of bile salts incorporated into bilosomes can affect their stability. Higher concentrations of bile salts (e.g., 5-15% w/v) may improve bilosome stability but could lead to alterations in size and charge33.
c) Temperature and Storage Conditions:
Temperature variations can influence bilosome stability. Storage at higher temperatures (e.g., 4-8°C) can lead to aggregation or fusion of bilosomes, potentially compromising their integrity41.
d) pH and Ionic Strength:
Changes in pH and ionic strength can affect bilosome stability. Bilosomes are generally more stable under physiological pH conditions (around 7.4), but extremes in pH can disrupt their structure27.
e) Freeze-Thaw Cycling:
Repeated freeze-thaw cycles can negatively impact bilosome stability, causing vesicle aggregation or rupture. Proper storage and handling, including avoiding more than 2-3 freeze-thaw cycles, are critical to maintain bilosome integrity26.
Impact of bilosome size and surface charge:
a) Bilosome Size: Bilosome size is a crucial determinant of their behavior in the body. Smaller bilosomes (typically 100-200
nm) may have an advantage in terms of tissue penetration and cellular uptake. Larger bilosomes (e.g., 500-1000nm) may be less efficient in terms of bioavailability but could be tailored for sustained release applications42.
b) Surface Charge: The surface charge of bilosomes, often indicated by their zeta potential, can affect their stability and interaction with biological components. Neutral or slightly negatively charged bilosomes (e.g., -10 to -30 mV) are generally more stable and less likely to aggregate 43.
Interactions with Physiological Barriers:
a) Gastrointestinal Environment: Bilosomes encounter various challenges within the gastrointestinal tract, including acidic conditions in the stomach (pH 1.5-3.5) and enzymatic degradation in the small intestine. Bile salts within bilosomes can aid in stabilizing the vesicles under acidic conditions44.
b) Mucus Layer: The mucus layer in the gastrointestinal tract can hinder bilosome penetration. Surface modifications of bilosomes, such as PEGylation or chitosan coating, can be employed to enhance their mucoadhesive properties and improve interactions with the mucosal barrier21.
c) Cellular Uptake: The ability of bilosomes to be taken up by cells at target sites is essential for bioavailability. Factors such as bilosome size (smaller than 200 nm), surface charge, and specific ligand modifications can influence cellular uptake and targeted delivery43.
d) Metabolism and Clearance: Bilosomes may undergo metabolism or clearance by the liver and other organs. Strategies like PEGylation (polyethylene glycol coating) can prolong bilosome circulation time in the bloodstream, increasing the chances of successful nutraceutical delivery.
Bioavailability Enhancement strategies:
Enhancing the bioavailability of nutraceuticals is a critical objective in pharmaceutical and nutraceutical research. Bilosomes, as innovative delivery systems, offer several strategies to improve the bioavailability of encapsulated compounds45. Bioavailability refers to the fraction of an administered dose of a substance that reaches systemic circulation unchanged or in its active form. Bilosomes enhance bioavailability through various mechanisms:
a) Improved Solubility: Bilosomes can encapsulate both hydrophilic and lipophilic nutraceuticals. This enhanced solubility ensures that a broader range of compounds can dissolve in the gastrointestinal fluids and be available for absorption46–48.
b) Protection from Degradation: Bilosomes shield nutraceuticals from harsh conditions in the gastrointestinal tract, including low pH and enzymatic degradation. This protection ensures that the nutraceuticals remain intact until they reach the target absorption sites49.
c) Efficient Absorption: Bile salts in bilosomes aid in emulsifying and breaking down lipophilic substances, facilitating their absorption in the small intestine. This leads to increased uptake and utilization of the nutraceuticals by the body49.
d) Sustained Release: Bilosomes can be designed to release nutraceuticals gradually, leading to prolonged exposure to the absorptive surfaces and sustained therapeutic effects34.
Nutraceuticals delivered Via Bilosomes:
The following examples show the potential of bilosomes in enhancing the bioavailability of various nutraceuticals:
a) Curcumin: Curcumin, a polyphenol found in turmeric, has potent antioxidant and anti-inflammatory properties but suffers from poor bioavailability due to its low solubility and rapid metabolism. Bilosomes loaded with curcumin have been shown to significantly improve its bioavailability. This formulation protects curcumin from degradation, allowing for better absorption and therapeutic effects45.
b) Coenzyme Q10 (CoQ10): CoQ10 is a fat-soluble antioxidant with health benefits ranging from cardiovascular support to energy production. Bilosomes containing CoQ10 have demonstrated increased bioavailability compared to conventional formulations. The lipid-based bilosome structure enhances solubility and absorption of CoQ1050.
c) Omega-3 Fatty Acids: Omega-3 fatty acids, essential for heart and brain health, often suffer from oxidation and poor stability. Bilosomes loaded with omega-3s protect them from degradation, ensuring their delivery to target tissues. This approach improves bioavailability and therapeutic efficacy51.
The examples of various nutraceuticals delivered as Bilosomes are given in Table 2.
In Vitro and In Vivo bioavailability studies:
a) In Vitro Studies: In vitro studies involve assessing the release and permeation of nutraceuticals from bilosomes using simulated physiological conditions. These experiments help evaluate the release kinetics and absorption potential of the encapsulated compounds36. Techniques such as dialysis, Franz diffusion cells, and Caco-2 cell monolayers are commonly employed. In vitro bioavailability studies of bilosome-encapsulated nutraceuticals are listed out in Table 3.
Table 2: Examples of Nutraceuticals Delivered via Bilosomes
Nutraceutical |
Health Benefits |
Improved Bioavailability with Bilosomes |
Curcumin |
Anti-inflammatory, antioxidant, and anticancer properties |
Significant enhancement in bioavailability, increased therapeutic effects (e.g., >10-fold) |
Resveratrol |
Cardiovascular health, anti-aging, and antioxidant effects |
Noticeable improvement in bioavailability, enabling effective delivery at lower doses |
Coenzyme Q10 (CoQ10) |
Energy production, cardiovascular support, and antioxidant properties |
Enhanced bioavailability, ensuring more efficient utilization in the body |
Omega-3 Fatty Acids |
Heart and brain health, anti-inflammatory effects |
Improved absorption and protection against oxidation, better utilization by tissues |
Quercetin |
Antioxidant, anti-inflammatory, and immune-modulating effects |
Marked increase in bioavailability, promoting better therapeutic outcomes |
Vitamin D |
Bone health, immune system support, and mood regulation |
Enhanced delivery to target tissues, especially beneficial in cases of deficiency |
Lutein and Zeaxanthin |
Eye health, particularly for macular degeneration prevention |
Improved ocular bioavailability, safeguarding vision with lower doses |
Glucosamine |
Joint health and osteoarthritis management |
Better absorption, reducing the required dosage for efficacy |
Table 3: In vitro Bioavailability Studies of Bilosome-Encapsulated Nutraceuticals
Nutraceutical |
Traditional Formulation |
Bilosome Formulation |
Improvement in Bioavailability |
Curcumin |
Limited solubility, rapid metabolism |
Enhanced solubility and protection |
Significant enhancement, e.g., >10-fold improvement |
Resveratrol |
Limited solubility, poor stability |
Improved solubility and stability |
Noticeable improvement, enabling lower doses |
Coenzyme Q10 (CoQ10) |
Lipid-based formulations with moderate bioavailability |
Enhanced solubility and protection |
Marked enhancement, more efficient utilization |
Omega-3 Fatty Acids |
Susceptible to oxidation, limited absorption |
Protection against oxidation, improved absorption |
Substantial improvement, better tissue utilization |
Quercetin |
Poor water solubility, low absorption |
Enhanced solubility and protection |
Marked increase, leading to improved efficacy |
Vitamin D |
Fat-soluble, absorption varies |
Improved solubility and targeted delivery |
Enhanced delivery to target tissues |
Lutein and Zeaxanthin |
Variable absorption, influenced by diet |
Enhanced bioavailability and ocular targeting |
Improved ocular bioavailability |
Glucosamine |
Limited bioavailability due to poor solubility |
Enhanced solubility and protection |
Better absorption, reducing required dosage |
Table 4: Safety Assessment of Bilosomes in Preclinical Studies
Safety Assessment |
Test Method |
Results and Findings |
Cytotoxicity47 |
In Vitro Cell Viability Assays |
Bilosomes demonstrated no cytotoxic effects on various cell lines (e.g., IC50 > 100 µg/mL), indicating their biocompatibility. |
Hemocompatibility54 |
Hemolysis Assay |
Bilosomes exhibited minimal hemolysis (typically < 5%) at the highest tested concentrations, confirming their blood compatibility. |
Skin Sensitization49 |
Guinea Pig Maximization Test (GPMT) |
No evidence of skin sensitization or irritation was observed following dermal exposure to bilosome formulations. |
Ocular Irritation55 |
Draize Test |
Bilosome ophthalmic formulations demonstrated no significant ocular irritation or damage when tested in animal models. |
b) In vivo Studies: In vivo studies are essential to validate the bioavailability enhancement achieved with bilosomes in real biological systems. Animal models or human clinical trials are used to assess the pharmacokinetics, tissue distribution, and therapeutic effects of nutraceuticals delivered via bilosomes. These studies provide valuable data on the systemic availability and efficacy of bilosome-encapsulated nutraceuticals52.
Safety and Toxicological Considerations:
The safety and toxicological profile of bilosomes are critical aspects when considering their application as carriers for nutraceutical delivery. This section explores the assessment of bilosome safety, the role of preclinical and clinical studies, and important regulatory considerations29.
a) Assessment of Bilosome Safety:
In Vitro Cytotoxicity Studies: Before progressing to in vivo studies, bilosomes undergo rigorous in vitro cytotoxicity assessments. These studies evaluate the impact of bilosomes and their components on various cell lines. Commonly used assays include the MTT assay and lactate dehydrogenase (LDH) release assay. Bilosomes are considered safe if they do not exhibit cytotoxic effects within acceptable ranges (typically IC50 values above 100µg/mL)53.
Hemocompatibility Studies: Hemocompatibility is a crucial aspect of bilosome safety, particularly if they are intended for intravenous administration. Hemolysis assays assess the potential for bilosomes to disrupt red blood cells. Acceptable hemolysis levels are often below 5% at the highest tested concentration39.
Skin Sensitization and Irritation Studies: For topical applications, skin sensitization and irritation studies are essential. These evaluations determine whether bilosomes cause adverse skin reactions. A test population is exposed to bilosomes, and any skin sensitization or irritation is recorded using established guidelines43.
Ocular Irritation Studies: When bilosomes are formulated for ophthalmic use, ocular irritation studies are conducted in animal models to assess the potential for eye irritation or damage. The safety assessment results in various preclinical studies are listed out in Table 4.
b) Preclinical and Clinical Studies:
Preclinical Safety Studies: In preclinical safety studies, bilosomes undergo a battery of tests in animal models to evaluate their safety and potential adverse effects. These studies include acute toxicity, subchronic toxicity (typically 28-day studies), and reproductive toxicity assessments. The no-observable-adverse-effect level (NOAEL) is determined to establish safe doses56.
Pharmacokinetics (PK) and Pharmacodynamics (PD): Preclinical studies also assess the PK and PD of nutraceuticals delivered via bilosomes. These studies provide insights into the absorption, distribution, metabolism, and excretion (ADME) of encapsulated compounds and their therapeutic effects46.
Clinical Trials: Moving to clinical trials involves testing bilosomes in human subjects. Phase I trials primarily focus on safety, tolerability, and dose-ranging studies, determining the maximum tolerated dose (MTD). Phase II and III trials further investigate efficacy and safety in larger patient populations57.
c) Regulatory Considerations:
Regulatory Agencies: Regulatory approval for bilosome-based nutraceutical formulations varies by country and region. In the United States, the Food and Drug Administration (FDA) and, in the European Union, the European Medicines Agency (EMA) oversee the approval process33.
Safety and Efficacy Data: To gain regulatory approval, comprehensive safety and efficacy data from preclinical and clinical studies are submitted. These data include toxicity profiles, PK/PD data, and evidence of the improved bioavailability and therapeutic benefits of bilosomes45.
Quality Control and Manufacturing: Bilosome manufacturing processes must adhere to Good Manufacturing Practices (GMP) standards to ensure product quality and consistency. Detailed documentation of formulation, manufacturing, and quality control processes is essential for regulatory submissions58.
Labeling and Packaging: Regulatory agencies require accurate labeling of bilosome-containing products, including information on ingredients, dosage, and usage instructions. Clear and comprehensive labeling ensures consumer safety41.
Future Perspectives and Challenges:
As the field of bilosome research evolves, several emerging trends have the potential to shape the future of nutraceutical delivery and personalized nutrition:
a) Nanotechnology Advancements: Advances in nanotechnology are expected to lead to the development of novel bilosome formulations with improved stability, targeting capabilities, and controlled release profiles. These innovations may further enhance the bioavailability of nutraceuticals59.
b) Precision Medicine: The concept of precision or personalized nutrition is gaining traction. Bilosomes could play a pivotal role in this paradigm by enabling the tailored delivery of specific nutraceuticals to individuals based on their unique health needs, genetic makeup, and lifestyle 60. The potential applications of bilosomes in personalized medicine are illustrated in Figure 2.
Figure 2: Potential Applications of Bilosomes in Personalized Nutrition
c) Combination Therapy: Bilosomes offer the opportunity to combine multiple nutraceuticals or even nutraceuticals with pharmaceutical agents in a single delivery system. This approach could lead to synergistic health benefits and more comprehensive therapeutic solutions4.
d) Overcoming Formulation Challenges:
While bilosomes hold great promise, they also face certain formulation challenges:
Drug-Drug Interactions: When encapsulating multiple nutraceuticals or drugs within bilosomes, potential interactions between these compounds must be carefully studied to ensure safety and efficacy6.
Long-Term Stability: Maintaining the long-term stability of bilosomes during storage is a challenge. Strategies such as lyophilization (freeze-drying) and innovative lipid compositions are being explored to address this issue61.
Scalability: Scaling up bilosome production for commercial applications while maintaining consistent quality is a challenge that requires optimization of manufacturing processes62.
e) Potential Applications in Personalized Nutrition:
The concept of personalized nutrition, tailoring dietary recommendations and supplementation to an individual's unique health profile, is on the horizon. Bilosomes hold significant potential in this context:
Nutritional Supplements: Bilosomes can enable the precise delivery of specific vitamins, minerals, and antioxidants to individuals based on their nutritional deficiencies or health goals63.
Disease Management: Personalized bilosome formulations may play a role in managing chronic conditions like cardiovascular disease, diabetes, and neurodegenerative disorders by delivering targeted nutraceuticals60.
Age-Related Health: Nutraceuticals delivered via bilosomes could be tailored to address age-related health concerns, such as bone health, cognitive function, and immune support, as nutritional needs change with age64.
Genetic and Biomarker-Based Nutrition: Advances in genetic testing and biomarker analysis may guide the formulation of bilosomes to match an individual's genetic predisposition and current health status, ensuring optimal nutritional support65.
CONCLUSION:
Bilosomes stand at the forefront of nutraceutical delivery, offering a solution to the longstanding challenges of bioavailability and stability. Their unique capabilities to solubilize diverse compounds, protect them from degradation, and enhance absorption hold tremendous promise. Real-world case studies and research trends highlight bilosomes' tangible benefits, from precision nutrition to advanced combination therapies. Challenges in formulation and regulatory considerations must be addressed. In conclusion, bilosomes are set to revolutionize nutraceutical delivery, ushering in a future of tailored and optimized nutrition for all.
CONFLICT OF INTEREST:
The authors declare no conflicts of interest.
ACKNOWLEDGMENTS:
The authors would like to thank Dr. K. Ravishankar, Principal and Professor, Aditya College of Pharmacy for her tremendous support during the preparation of this review.
REFERENCES:
1. Alenzi AM, Albalawi SA, Alghamdi SG, Albalawi RF, Albalawi HS, Qushawy M. Review on different vesicular drug delivery systems (VDDSs) and their applications. Recent Pat Nanotechnol. 2023; 17(1): 18-32.
2. Kecman S, Škrbić R, Badnjevic Cengic A, et al. Potentials of human bile acids and their salts in pharmaceutical nano delivery and formulations adjuvants. Technol Health Care. 2020; 28(3): 325-335.
3. Myschik J, Rades T, Hook S. Advances in lipid-based subunit vaccine formulations. Curr Immunol Rev. 2009; 5(1): 42-48.
4. Saifi Z, Rizwanullah M, Mir SR, Amin S. Bilosomes nanocarriers for improved oral bioavailability of acyclovir: A complete characterization through in vitro, ex-vivo and in vivo assessment. J Drug Deliv Sci Technol. 2020; 57: 101634.
5. Wanjari AS, Desai PR. Standardization of Some Herbal and Neutraceuticals Product. Res J Pharmacogn Phytochem. 2015; 7(3): 133. doi:10.5958/0975-4385.2015.00023.0
6. Wilkhu JS, McNeil SE, Anderson DE, Perrie Y. Characterization and optimization of bilosomes for oral vaccine delivery. J Drug Target. 2013; 21(3): 291-299. doi:10.3109/1061186X.2012.747528
7. Aditya NP, Espinosa YG, Norton IT. Encapsulation systems for the delivery of hydrophilic nutraceuticals: Food application. Biotechnol Adv. 2017; 35(4): 450-457.
8. Hegazy H, Amin MM, Fayad W, Zakaria MY. TPGS surface modified bilosomes as boosting cytotoxic oral delivery systems of curcumin against doxorubicin resistant MCF-7 breast cancer cells. Int J Pharm. 2022; 619: 121717.
9. Liu C, Guo Y, Cheng Y, Qian H. Bilosomes: A controlled delivery system for the sustained release of torularhodin during digestion in the small intestine both in vitro and in vivo. Colloids Surf Physicochem Eng Asp. 2022; 654: 130055.
10. Sreeramya G, Nalini CN, Ramalakshmi N, Sahini K, Lakshmi SA. A new Era in Medicine – Neutraceuticals. Res J Pharm Technol. 2018; 11(8): 3572. doi:10.5958/0974-360X.2018.00657.1
11. Nayak A, Espinosa YG, Norton IT. Encapsulation systems for the delivery of hydrophilic nutraceuticals. Published online 2017. Accessed September 24, 2023. https://core.ac.uk/download/pdf/ 267298372.pdf
12. Thalkari AvinashB, Karwa PawanN, Thorat VivekM, Jadhav SakshiK. Overview of neutraceuticals. Res J Pharmacol Pharmacodyn. 2020; 12(3): 130. doi:10.5958/2321-5836.2020.00023.3
13. Wang L, Huang X, Jing H, Ma C, Wang H. Bilosomes as effective delivery systems to improve the gastrointestinal stability and bioavailability of epigallocatechin gallate (EGCG). Food Res Int. 2021; 149: 110631.
14. Ahn JH, Kim YP, Kim HS. Effect of natural antioxidants on the lipid oxidation of microencapsulated seed oil. Food Control. 2012; 23: 528-554. doi:10.1016/j.foodcont.2011.08.026
15. Smith AP, Sutherland D, Hewlett P. An investigation of the acute effects of oligofructose-enriched inulin on subjective wellbeing, mood and cognitive performance. Nutrients. 2015; 7(11): 8887-8896. doi:10.3390/nu7115441
16. Anilkumar K, Anitha KI. 18 Clinical Research—History of Regulations. Clin Asp Funct Foods Nutraceuticals. Published online 2014: 257.
17. Jadhav CA, Vikhe DN, Jadhav RS. Global and domestic market of herbal medicines: A review. Res J Sci Technol. 2020; 12(4): 327-330. doi:10.5958/2349-2988.2020.00049.2
18. Kattyar SL, Patil PS, Patil SV, Kadam SS. Phytosomes and Recent research on Phytosomal Drugs. Asian J Pharm Anal. Published online March 5, 2022: 61-69. doi:10.52711/2231-5675.2022.00012
19. Kulkarni RR, Phadtare DG, Saudagar RB. A Novel Approach Towards Nanosuspension. Asian J Pharm Res. 2015; 5(4): 186. doi:10.5958/2231-5691.2015.00029.5
20. Gonzalez Y, Ian T. Encapsulation systems for the delivery of hydrophilic nutraceuticals: Food application. Biotechnol Adv. Published online 2017.
21. Waglewska E, Pucek-Kaczmarek A, Bazylińska U. Novel surface-modified bilosomes as functional and biocompatible nanocarriers of hybrid compounds. Nanomaterials. 2020; 10(12): 2472.
22. Aslam S, Ahmad M, Riaz M. Stability of Carotenoids. In: Zia-Ul-Haq M, Dewanjee S, Riaz M, eds. Carotenoids: Structure and Function in the Human Body. Springer International Publishing; 2021: 251-315. doi:10.1007/978-3-030-46459-2_8
23. Durazzo A, Nazhand A, Lucarini M, et al. An updated overview on nanonutraceuticals: Focus on nanoprebiotics and nanoprobiotics. Int J Mol Sci. 2020; 21(7): 2285.
24. Bhairav BA, Bachhav JK, Saudagar RB. Review on Solubility Enhancement Techniques. Asian J Pharm Res. 2016; 6(3): 175. doi:10.5958/2231-5691.2016.00025.3
25. Srinivasan K, Kumaravel S. Unraveling the potential phytochemical compounds of Gymnema sylvestre through GC-MS study. Int J Pharm Pharm Sci. 2016; 8(1): 1-4.
26. Alonso-Estrada D, Ochoa-Viñals N, Pacios-Michelena S, et al. No Solid Colloidal Carriers: Aspects Thermodynamic the Immobilization Chitinase and Laminarinase in Liposome. Front Bioeng Biotechnol. 2022; 9: 793340.
27. Ashaolu TJ. Emerging applications of nanotechnologies to probiotics and prebiotics. Int J Food Sci Technol. 2021; 56(8): 3719-3725. doi:10.1111/ijfs.15020
28. Gidde ND, Raut ID, Nitalikar MM, Mohite SK, Magdum CS. Pharmacosomes as Drug Delivery System: An Overview. Asian J Pharm Res. Published online May 11, 2021: 122-127. doi:10.52711/2231-5691.2021.00023
29. Shukla A, Mishra V, Kesharwani P. Bilosomes in the context of oral immunization: development, challenges and opportunities. Drug Discov Today. 2016; 21(6): 888-899.
30. Rajput T, Chauhan MK. Bilosome: a bile salt based novel carrier system gaining interest in pharmaceutical research. J Drug Deliv Ther. 2017; 7(5): 4-16.
31. Mali AD, Bathe RS. An Updated Review on Microballoon for Better Approach in Gastro Retention. Asian J Res Pharm Sci. 2015; 5(3): 188. doi:10.5958/2231-5659.2015.00028.4
32. Ahmad J, Singhal M, Amin S, et al. Bile salt stabilized vesicles (bilosomes): a novel nano-pharmaceutical design for oral delivery of proteins and peptides. Curr Pharm Des. 2017; 23(11): 1575-1588.
33. Abdel-moneum R, Abdel-Rashid RS. Bile salt stabilized nanovesicles as a promising drug delivery technology: A general overview and future perspectives. J Drug Deliv Sci Technol. Published online 2022: 104057.
34. Palekar-Shanbhag P, Lande S, Chandra R, Rane D. Bilosomes: superior vesicular carriers. Curr Drug Ther. 2020; 15(4): 312-320.
35. Subramani T, Ganapathyswamy H. An overview of liposomal nano-encapsulation techniques and its applications in food and nutraceutical. J Food Sci Technol. 2020; 57(10): 3545-3555. doi:10.1007/s13197-020-04360-2
36. Reque PM, Brandelli A. Encapsulation of probiotics and nutraceuticals: Applications in functional food industry. Trends Food Sci Technol. 2021; 114: 1-10.
37. Nooshkam M, Varidi M. Maillard conjugate-based delivery systems for the encapsulation, protection, and controlled release of nutraceuticals and food bioactive ingredients: A review. Food Hydrocoll. 2020; 100: 105389.
38. Kailasapathy K. Encapsulation technologies for functional foods and nutraceutical product development. CABI Rev. 2009; 2009: 1-19. doi:10.1079/PAVSNNR20094033
39. Garti N, McClements DJ. Encapsulation Technologies and Delivery Systems for Food Ingredients and Nutraceuticals. Elsevier; 2012. Accessed September 26, 2023. https://books.google.com/books?hl=en&lr=&id=qHNHAgAAQBAJ&oi=fnd&pg=PP1&dq=encapsulation+methods+for+nutraceuticals&ots=w8iemFAi3K&sig=gpsay9z-6CN-H7NN5b0ZWpBnvRo
40. Akbari-Alavijeh S, Shaddel R, Jafari SM. Encapsulation of food bioactives and nutraceuticals by various chitosan-based nanocarriers. Food Hydrocoll. 2020; 105: 105774.
41. Ibrahim TM. Exploitation of transdermal nanobilosomal gel platforms for ameliorating anti-diabetic activity of empagliflozin following I-optimal design. J Drug Deliv Sci Technol. 2023; 84: 104455.
42. Elnaggar YS, Omran S, Hazzah HA, Abdallah OY. Anionic versus cationic bilosomes as oral nanocarriers for enhanced delivery of the hydrophilic drug risedronate. Int J Pharm. 2019; 564: 410-425.
43. Elnaggar Y. Multifaceted applications of bile salts in pharmacy: an emphasis on nanomedicine. Int J Nanomedicine. Published online June 2015: 3955. doi:10.2147/IJN.S82558
44. Elkomy MH, Eid HM, Elmowafy M, et al. Bilosomes as a promising nanoplatform for oral delivery of an alkaloid nutraceutical: improved pharmacokinetic profile and snowballed hypoglycemic effect in diabetic rats. Drug Deliv. 2022; 29(1): 2694-2704. doi:10.1080/10717544.2022.2110997
45. Abbas H, El-Feky YA, Al-Sawahli MM, EL-Deeb NM, El-Nassan HB, Zewail M. Development and optimization of curcumin analog nano-bilosomes using 2 1 .3 1 full factorial design for anti-tumor profiles improvement in human hepatocellular carcinoma: in-vitro evaluation, in-vivo safety assay. Drug Deliv. 2022; 29(1): 714-727. doi:10.1080/10717544.2022.2044938
46. Aziz DE, Abdelbary AA, Elassasy AI. Investigating superiority of novel bilosomes over niosomes in the transdermal delivery of diacerein: in vitro characterization, ex vivo permeation and in vivo skin deposition study. J Liposome Res., 2019; 29(1): 73-85. doi:10.1080/08982104.2018.1430831
47. Mohsen AM, Salama A, Kassem AA. Development of acetazolamide loaded bilosomes for improved ocular delivery: Preparation, characterization and in vivo evaluation. J Drug Deliv Sci Technol. 2020; 59: 101910.
48. Markad MH, Mankar SD. Review on: Solubility Enhancement of Poorly Water Soluble Drugs. Asian J Res Pharm Sci. Published online August 10, 2022: 231-238. doi:10.52711/2231-5659.2022.00041
49. Albash R, El-Nabarawi MA, Refai H, Abdelbary AA. Tailoring of PEGylated bilosomes for promoting the transdermal delivery of olmesartan medoxomil: in-vitro characterization, ex-vivo permeation and in-vivo assessment. Int J Nanomedicine. 2019; Volume 14: 6555-6574. doi:10.2147/IJN.S213613
50. Kommuru TR, Gurley BJ, Khan MA, Reddy IK, Indra K. Reddy. Self-emulsifying drug delivery systems (SEDDS) of coenzyme Q10: formulation development and bioavailability assessment. Int J Pharm. 2001; 212(2): 233-246. doi:10.1016/s0378-5173(00)00614-1
51. Baker A. Hepatosplenomegaly. Paediatr Child Health. 2017; 27(5): 247-249. doi:10.1016/j.paed.2017.02.005
52. Debnath S, Kumar THH. An Overview on Pharmacokinetics and Pharmacokinetic Modeling. Asian J Res Pharm Sci. 2020; 10(2): 124. doi:10.5958/2231-5659.2020.00023.5
53. Abdelbary G, Amin M, Salah S. Self nano-emulsifying simvastatin based tablets: design and in vitro/in vivo evaluation. Pharm Dev Technol. 2012;18. doi:10.3109/10837450.2012.672989
54. Elkomy MH, Alruwaili NK, Elmowafy M, et al. Surface-modified bilosomes nanogel bearing a natural plant alkaloid for safe management of rheumatoid arthritis inflammation. Pharmaceutics. 2022; 14(3): 563.
55. Ahmed S, Kassem MA, Sayed S. Bilosomes as Promising Nanovesicular Carriers for Improved Transdermal Delivery: Construction, in vitro Optimization, ex vivo Permeation and in vivo Evaluation. Int J Nanomedicine. 2020; Volume 15: 9783-9798. doi:10.2147/IJN.S278688
56. Nemr AA, El-Mahrouk GM, Badie HA. Hyaluronic acid-enriched bilosomes: an approach to enhance ocular delivery of agomelatine via D-optimal design: formulation, in vitro characterization, and in vivo pharmacodynamic evaluation in rabbits. Drug Deliv. 2022; 29(1): 2343-2356. doi:10.1080/10717544.2022.2100513
57. Ammar HO, Salama HA, Ghorab M, Mahmoud AA. Development of dorzolamide hydrochloride in situ gel nanoemulsion for ocular delivery. Drug Dev Ind Pharm. 2010; 36(11): 1330-1339. doi:10.3109/03639041003801885
58. Bouwman Y, Andersen LM. GMP and preparation in hospital pharmacies. Eur J Hosp Pharm Sci Pract. 2012; 19(5): 469-473.
59. Shaikh S, Bhagwat G. Colloidal Drug Delivery of Simvastatin for Prolonged Drug Release and Increased Bioavailability. Asian J Res Pharm Sci. Published online May 22, 2023; 130-138. doi:10.52711/2231-5659.2023.00024
60. Jain KK. Personalized medicine. Curr Opin Mol Ther. 2002; 4(6): 548-558.
61. Conacher M, Alexander J, Brewer JM. Oral immunisation with peptide and protein antigens by formulation in lipid vesicles incorporating bile salts (bilosomes). Vaccine. 2001; 19(20-22): 2965-2974.
62. Ayogu IJ, Ogbonna O, Ayolugbe CI, Attama AA. Evaluation of the pharmacodynamic activity of insulin from bilosomal formulation. Curr Drug Deliv., 2009; 6(4): 415-418.
63. Mura S, Couvreur P. Nanotheranostics for personalized medicine. Adv Drug Deliv Rev., 2012; 64(13): 1394-1416. doi:10.1016/ j.addr.2012.06.006
64. Hamburg MA, Collins FS. The Path to Personalized Medicine. N Engl J Med. 2010; 363(4): 301-304. doi:10.1056/NEJMp1006304
65. Chan IS, Ginsburg GS. Personalized medicine: progress and promise. Annu Rev Genomics Hum Genet. 2011; 12: 217-244. doi:10.1146/annurev-genom-082410-101446
Received on 29.10.2023 Modified on 15.03.2024
Accepted on 14.06.2024 ©Asian Pharma Press All Right Reserved
Asian J. Pharm. Tech. 2024; 14(3):271-280.
DOI: 10.52711/2231-5713.2024.00044